FedEx Corp (NYSE:FDX) stock is down 2% to trade at $237.44 at last check, after a downgrade from J.P. Morgan Securities to "neutral" from "overweight." The firm also lowered its price target to $274 from $284, with the analyst in coverage noting the high cost of separating the freight segment, as well as recent operational underperformance.Plenty of analysts lean bullish toward FDX, with 18 of the 30 in question rating it a "buy" or better before today's adjustments. Plus, the 12-month consensus target pric ...

Group 1 - GE Vernova Inc. shares fell over 2% after RBC Capital downgraded the stock to Sector Perform from Outperform [1] - RBC Capital cut the price target for GE Vernova to $605 from $631 [1] - The downgrade reflects that the strong demand in energy generation and distribution, along with favorable pricing and productivity gains, are already priced into the stock's valuation and consensus forecasts [1] Group 2 - The $605 price target is based on 13 times RBC's 2030 EBITDA forecast of $12.2 billion, which is approximately 4% below consensus estimates [2]

Core Viewpoint - BMO analyst Fadi Chamoun has downgraded UPS shares from Buy to Hold, indicating a more cautious outlook on the company's performance [1]. Summary by Category Analyst Rating Changes - The rating on UPS shares has been cut to Hold from Buy [1]. - The price target for UPS shares has been reduced from $125 to $96 [1].

Core Viewpoint - Evercore ISI has downgraded FedEx shares from Buy to Hold, indicating a shift in investment sentiment towards the company [1] Company Summary - The downgrade reflects concerns regarding FedEx's future performance and market conditions that may impact its profitability [1]

Core Viewpoint - Jefferies analyst David Windley downgraded Icon PLC (ICLR.US) from "Buy" to "Hold" and reduced the target price from $220 to $175, citing excessive unfavorable factors facing the company [1] Group 1: Company Performance - Windley believes that despite Icon PLC's stock being "cheap," there may be further downward revisions to earnings expectations [1] - Ongoing channel surveys indicate that Icon PLC is losing market share, which undermines the growth momentum gained from winning four partnership agreements since the merger with PRA Health [1] Group 2: Financial Outlook - Jefferies estimates that the amount of customer order cancellations in the third quarter could approach $1 billion, with a possibility of maintaining high levels in the fourth quarter [1] Group 3: Company Overview - Icon PLC is a clinical research organization that provides outsourced research and development services for the biotechnology, pharmaceutical, and medical device industries, focusing on managing, developing, and analyzing clinical development-related projects [1]

Group 1 - Goldman Sachs downgraded Novartis' stock rating from "Neutral" to "Sell," indicating a negative outlook for the stock [1] - The target price for Novartis was slightly reduced from 95.00 CHF to 94.00 CHF, suggesting a weak price trajectory over the next 12 months [1] - Concerns were raised regarding Novartis' growth rate due to increasing competition in the generic drug market, leading to a structural adjustment in overall growth expectations [1] Group 2 - Despite growth concerns, Novartis maintains a strong financial health score, with a revenue growth of 12.95% over the past twelve months [1] - Current trading prices for Novartis are around 101 CHF in Europe and 127.70 USD in the US ADR market [1] - The stock's performance includes a pre-market decline of nearly 3%, with a recent pre-market price of 124.18 USD [1]

Group 1 - Bank of America has lowered the target price for Novavax from $9 to $7, changing its rating from "Neutral" to "Underperform" [2] - Citigroup has initiated coverage on Novavax with a "Sell" rating and a target price of $6 [2]

Group 1 - The stock of the company, CSPC Pharmaceutical Group, fell over 5%, marking the largest decline in three weeks [1] - Jefferies downgraded the stock rating to "underperform," indicating that all positive factors have already been reflected in the stock price [1] - The company continues to face sales challenges for key products [1]